SEATTLE--(BUSINESS WIRE)--Aug. 6, 2018--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on
discovering and developing innovative immunotherapies to treat cancer,
autoimmune/inflammatory, and other diseases, today announced the company
will present a business overview and update at the 2018 Wedbush PacGrow
Healthcare Conference on Tuesday, August 14, 2018 at 3:40 pm Eastern
Time in New York, NY.
A live webcast of the presentation will be available online in the
investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events.
A replay of the presentation will be available on the company website
for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel
protein-based immunotherapies using its proprietary Variant Ig Domain
(vIgD) technology. Our scientific platform is designed to interact with
multiple targets, including many present in the immune synapse. Alpine’s
vIgDs are developed using a process known as directed evolution, which
produces proteins capable of either enhancing or diminishing an immune
response and thereby may potentially apply therapeutically to cancer,
autoimmune, and inflammatory diseases. Alpine has also developed
Transmembrane Immunomodulatory Protein (TIP) technology, based on the
vIgD technology, to potentially enhance engineered cellular therapies.
For more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180806005529/en/
Source: Alpine Immune Sciences, Inc.
Pure Communications, Inc.